Inhibition of P-glycoprotein function by procyanidine on blood-brain barrier

Phytotherapy Research

Volumn 23, Issue 7, 2009, Pages 933-937

  He, Ling ^a   Zhao, Chuan ^a   Yan, Ming ^a   Zhang, Lu Yong ^a   Xia, Yuan Zheng ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Blood brain barrier; Cerebral tumor; P glycoprotein; Procyanidine

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CYCLOSPORIN A; DOXORUBICIN; GLYCOPROTEIN P; NIMUSTINE; PHOSPHATE; PROCYANIDIN; RHODAMINE 123; VERAPAMIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CELL; BRAIN TUMOR; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; LIFE EXTENSION; MEMBRANE VESICLE; MOUSE; NONHUMAN; PROTEIN FUNCTION; RAT; SPECTROFLUOROMETRY;

ADENOSINE TRIPHOSPHATASES; ANIMALS; BIFLAVONOIDS; BLOOD-BRAIN BARRIER; CATECHIN; CELLS, CULTURED; ENDOTHELIAL CELLS; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; P-GLYCOPROTEIN; PINUS; PLANT EXTRACTS; PROANTHOCYANIDINS; RATS; RHODAMINE 123; VERAPAMIL;

MUS MUSCULUS; PINUS MASSONIANA; RATTUS;

EID: 67650123176     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2781     Document Type: Article

References (23)

1. Abbott NJ. 2002. Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat 200: 629-638. (Pubitemid 34823054)
2. Antunes L, Angioi-Duprez KS, Bracard SR et al. 2000. Analysis of tissue chimerism in nude mouse brain and abdominal xenograft models of human glioblastoma multiforme: what does it tell us about the models and about glioblastoma biology and therapy? J Histochem Cytochem 48: 847-858.
3. Audus KL, Borchardt RT. 1986. Characterization of an in vitro blood-brain barrier model system for studying drug transport and metabolism. Pharm Res 3: 81-87. (Pubitemid 17191154)
4. Boulton DW, DeVane CL, Liston HL, Markowitz JS. 2002. In vitro P-glycoprotein affinity for atypical and conventional anti-psychotics. Life Sci 71: 163-169.
5. Chan LM, Lowes S, Hirst BH. 2004. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 21: 25-51. (Pubitemid 38050202)
6. Choo EF, Leake B, Wandel C et al. 2000. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 28: 655-660. (Pubitemid 30390404)
7. Eneroth A, Astrom E, Hoogstraate J et al. 2001. Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction. Eur J Pharm Sci 12: 205-214.
8. Engebraaten O, Hjortland GO, Hirschberg H, Fodstad O. 1999. Growth of precultured human glioma specimens in nude rat brain. J Neurosurg 90: 125-132. (Pubitemid 29024749)
9. Fontaine M, Elmquist WF, Miller DW. 1996. Use of rhodamine 123 to examine the functional activity of P-glycoprotein in primary cultured brain microvessel endothelial cell monolayers. Life Sci 59: 1521-1531. (Pubitemid 26358270)
10. Goldstein GW, Betz AL. 1986. The blood-brain-barrier. Sci Am 255: 74-83.
11. He L, Liu GQ. 2002. Interaction of multidrug resistance reversal agents with P-glycoprotein ATPase activity on blood-brain barrier. Acta Pharmacol Sin 23: 423-429. (Pubitemid 34467969)
12. Hegmann EJ, Bauer HC, Kerbel RS. 1992. Expression and functional activity of P-glycoprotein in cultured cerebral capillary endothelial cells. Cancer Res 52: 6969-6975. (Pubitemid 23006310)
13. Jette L, Murphy GF, Leclerc JM. 1995. Interaction of drugs with P-glycoprotein in brain capillaries. Biochem Pharmacol 50: 1701-1709.
14. Ji BS, He L, Li XQ, Liu GQ. 2006. CJZ3, a lomerizine derivative, modulates P-glycoprotein function in rat brain microvessel endothelial cells. Acta Pharmacol Sin 27: 414-418.
15. Lin JH, Yamazaki M. 2003. Role of P-glycoprotein in pharmacokinetics - clinical implications. Clin Pharmacokinet 42: 59-98. (Pubitemid 36092258)
16. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
17. Mayer U, Wagenaar E, Beijnen JH et al. 1996. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br J Pharmacol 119: 1038-1044. (Pubitemid 26366502)
18. Robert J. 1997. Multidrug resistance reversal agents. Drugs Future 22: 149-158.
19. Sarver JG, Klis WA, Byers JP, Erhardt PW. 2002. Microplate screening of the differential effects of test agents on Hoechst 33342, rhodamine 123, and rhodamine 6G accumulation in breast cancer cells that overexpress P-glycoprotein. J Biomol Screen 7: 29-34. (Pubitemid 34208860)
20. Schinkel AH, Smit JJ, van Tellingen O et al. 1994. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491-502. (Pubitemid 24153990)
21. Tsuji A, Terasaki T, Takabatake Y, Tenda Y, Tamai I, Yamashima T. 1992. P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci 51: 1427-1437.
22. Twentyman PR, Rhodes T, Rayner S. 1994. A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes. Eur J Cancer 30A: 1360-1369. (Pubitemid 24322076)
23. Wolburg H, Lippoldt A. 2002. Tight junctions of the blood-brain barrier: development, composition and regulation. Vasc Pharmacol 38: 323-337. (Pubitemid 36398254)